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An efficacious topical treatment for cutaneous leishmaniasis (CL) is highly desirable but still an ongoing chal-
lenge. Systemic risedronate (Ris) has been reported to have anti-leishmanial properties and Eudragit EPO (EuE)
has shown in vitro activity against L. (L.) amazonensis. The aim of this work was to investigate the in vivo efficacy of
topical Ris and EuE-Ris complexes on CL. Surface charge and Ris release kinetics from the different dispersions
were analyzed. BALB/c mice were infected intradermally with promastigotes of L. (L.) amazonensis. Ulcers were
treated with Ris or EuE-Ris hydrogels. All the lesions that received topical Ris or EuE-Ris showed an improvement
with respect to control: reduction of ulcer average size, cicatrization, flattened edges and no signs of necrosis. In
addition, a marked parasitic inhibition of 69.5 and 73.7% was observed in the groups treated with Ris and EuE-
Ris, respectively, with the IgG2a levels indicating a tendency towards cure. The results are promising and the
system should now be enhanced to achieve total parasite elimination.1. Introduction
Leishmaniasis is, according to the World Health Organization, one of
the most important tropical orphan diseases. This is due to inadequate
treatments, especially in the case of rural populations [1]. The cutaneous
form is the most prevalent, with an annual incidence of 1–1.5 million
cases, and is endemic in 98 countries [2]. Its lesions are characterized by
nodules, which sometimes progress to ulcers. Changes in the skin reflect
the immune response to the infection, resulting in hyperplasia, epidermal
thickening, and commonly a strong inflammation with destruction of the
epidermis resulting in an ulcer [3].
The current first line pharmacotherapy involves the use of pentava-
lent antimonials, which have a high toxicity and significant side-effects,
administered parentally or orally [4, 5]. A standard therapy involves
daily intramuscular injections for 20–30 days, which is distressing and
requires specialized professionals. An efficacious topical treatment would(D.C. Carrer), barrosopaola75@
e.
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is an open access article under timprove patient compliance due to ease of use, diminished hurt,
decreased side effects and the possibility of use in a rural context with
low medical infrastructure. Depending on the size or number of the le-
sions, topical paromomycin ointment may be recommended, with several
topical formulations of paromomycin having been developed for the
treatment of CL with variable results [6, 7, 8]. Nevertheless, there is still
no commercial formulation available.
Macrophage-like cells, or osteoclasts, are targets of bisphosphonate
antiresorptive drugs, and it has been observed that risedronate (Ris) have
considerable activity against leishmania parasites. The literature shows
Ris anti-leishmanial efficacy in vitro in amastigotes strain of L. (L.)
donovani, and low toxicity indices in macrophages [9]; efficacy was also
demonstrated in promastigotes strain of L. infantum [10]. The in vivo
efficacy of Ris was demonstrated in a visceral leishmaniasis (L. (L.)
donovani) model of mice after its intra-peritoneal administration [11],
with more than 85 % suppression of the amastigotes load in the liver,gmail.com (P.A. Barroso).
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as pamidronate after intra-peritoneal administration has also been
described in a cutaneous leishmaniasis model (L. mexicana amazonensis),
with the disappearance of the lesions and more than 99 % of the amas-
tigotes at the site of the lesion [12]. However, Ris topical efficacy in
cutaneous leishmaniasis (CL) has not yet been tested.
Eudragit EPO (EuE, a basic polyelectrolyte) has shown good in vitro
activity in an L. (L.) amazonensismodel with a high selectivity index [13].
In vitro studies have shown that the complexation of Ris with EuE gives
rise to a new material, referred to as EuE-Ris, which has advantageous
properties. These include high loading capacity and high affinity for the
phosphonate groups of the drug, leading to a controlled Ris release [14].
This material has also shown a reduction in the topical irritation potential
in a gastric model.
In the present study, our aim was to investigate the efficacy of topical
administration of Ris and EuE-Ris complexes in an animal model of CL.
2. Materials and methods
2.1. Preparation of EuE-Ris and Ris hydrogels
A Ris (risedronate monosodium monohydrate, kindly provided by
IVAX Argentina S.A.) aqueous solution was first prepared. Then, in order
to facilitate its topical application, hydroxypropyl methylcellulose
(HPMC, Parafarm®, Argentina) was added to the Ris solution, producing
a hydrogel. A final concentration of 2 % HPMC and 20 mg/mL of Ris was
obtained. This concentration was selected according to doses used in the
literature for experimental leishmaniasis i.p. formulations [9, 11].
The EuE-Ris complex was prepared as previously described in Guz-
man et al. [14]. HPMC was added to an aqueous dispersion of this
complex, to give an hydrogel with a final concentration of 20 mg/mL of
Ris, 40 mg/mL of EuE and 2 % of HPMC. Both hydrogels are thus named
Ris-HPMC and EuE-Ris-HPMC respectively.2.2. EuE-Ris-HPMC and Ris-HPMC hydrogels physicochemical
characterization
The pH was determined in all the systems obtained, using a Mettler
Toledo Seven Multi pH meter equipped with a combined Ag/AgCl elec-
trode (Mettler Toledo DG 115-SC). The surface charge was analyzed
using a Zetasizer NanoSerie DTS 1060 (Malvern Instruments S.A., Wor-
cestershire, UK). The hydrogels were diluted (1:10) in deionized water,
and zeta potential (ZP) was determined at 25 C in triplicate.
Bicompartimental Franz cells were used to study the release behavior
of the hydrogels obtained. One (1) mL of EuE-Ris-HPMC (pH ¼ 5.5) and
Ris-HPMC (pH ¼ 5.2) containing 5 mg of Ris was used. An aqueous Ris
solution (pH ¼ 4.8) and EuE-Ris (pH ¼ 4.7) dispersion containing
equivalent Ris concentration were used as references. Ris concentration
for the assay was selected in order to reach sink conditions. For that, the
volume of the receptor compartment, sampling frequency and concen-
tration of Ris in the donor compartment were considered. The experi-
ments were performed as described in Guzman et al [14] with the
receptor compartment filled with milli Q water or physiological solution
(NaCl 0.9 %). Ris concentrations were determined by UV spectroscopy at
λ ¼ 262 nm. For comparison, Ris release slopes from Ris solutions were
used. Slopes were calculated using the initial portion of the linear section
of the curve.2.3. In vivo anti-leishmanial efficacy of hydrogels
2.3.1. Leishmania parasites
L. (L.) amazonensis promastigotes (MHOM/BR/73/M2269) were
taken from liquid nitrogen stocks and maintained by serial passages in
the tail base of BALB/c mice. Isolation was performed by seeding lesion2
homogenates in Difco blood agar (USMARU) medium containing 20 % of
defibrinated rabbit blood plus Proline Balanced Salt Solution (PBSS)
containing 100 U/mL penicillin and 50 μg/mL streptomycin (P–S, Invi-
trogen Life Technologies, Carlsbad, CA, USA.) at 24 C. During the sta-
tionary phase, parasites were harvested, washed in PBSS pH 7 with 1 %
penicillin/streptomycin, and re-suspended in PBSS at the concentration
required for mice inoculation.
2.3.2. Animal model
BALB/c female mice (6–8 weeks old) from the Animal Facility of the
Institute of Experimental Pathology, Salta, Argentina were used. Animals
were infected according to Peralta et al protocol [15]. The base of the tail
was intradermally inoculated in with 1–2 x 107 parasites (50 μL), and
after approximately five weeks of inoculation, the lesions became
ulcerated.
Animals were maintained in a controlled environment of 55 % rela-
tive humidity and 26 C, with food and water ad libitum. All animal
protocols were approved by the Institutional Committee for the Care and
Use of Laboratory Animals of the School of Health of Universidad
Nacional de Salta, Argentina (Res. CD N 745-17). This study also com-
plies with the Arrive guide for the care and use of laboratory animals
[16].
2.3.3. Treatments
Animal treatments started five weeks after infection, when the lesions
had become ulcerated. A 100 μL dose of hydrogel containing 2 mg Ris or
an equivalent dose from EuE-Ris complex was applied with a syringe and
spread over the lesion. Two doses a day were applied 5 days a week for 22
days and the mice were observed after gel administration for approx. 30
minutes.
Animals were divided into the following three groups: group 1
received Ris-HPMC hydrogel; group 2 was given EuE-Ris-HPMC hydrogel;
and the control animal group (group 3) received no treatment. Each
experimental group had 5 mice.
2.3.4. Lesion size
Lesion areas (ulcers) were determined by measuring the ulcer di-
ameters throughout the treatment (over 22 days) with a digital caliper.
Two diameters (L and W; at right angles to each other) of the ulcer were
measured, and the size (mm2) was determined according to Eq. (1).
Lesion size ðLSÞ¼ ðL *WÞ = ð4 *ΠÞ (1)
Results are informed as each group's lesion average area for each day's
treatment. The area of lesions with completely flattened edges was taken
to be 0 mm2.
2.3.5. Lesion macroscopic appearance
Animal lesions were photographed at the end of treatment and clas-
sified in terms of severity. At the beginning of the experiment, all lesions
were ulcers. Flattened edges were considered to be a sign of cure of the
lesion.
Leishmania related lesions are initially papular. Gradually they take
on a darker reddish tone, while becoming infiltrated and bigger. The
lesions then progress into nodular lesions, or a deeply infiltrated plaque,
at the center of which a seropurulent exudate begins to sprout, whose
desiccation may give rise to a tightly adhering scab. In this phase, the
ulcerative lesion may have a variable dimension; the skin that covers it
has a wine-violaceous red tone and is often surrounded by an edematous
and indurated area. Dermal necrosis may also be seen [17].
The stages of the lesions, which are related to their severity, were
classified as follows:
a) Necrotic ulcer: dry and regular rounded edges with lesions having a
dark red/black color in the center.
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which sprouts a seropurulent exudate, with thick high borders.
c) Partially flattened edges: ulcerated lesion that begins to heal and
flatten, but still having an ulcerated area that is less than 50 % of the
initial area.
d) Flattened edges: where the ulcer has disappeared and the edges are
flattened in the whole perimeter of the lesion.
2.3.6. Immunoglobulin levels
At the end of treatment, blood was extracted in order to measure
immunoglobulin levels.
Parasite-specific IgG1 and IgG2a from serumwere measured by ELISA
as described in a previous work [15].
2.3.7. Smears
The presence of parasites in the lesions was examined after sacrificing
the animals. Skin tissue samples were aseptically excised with scissors,
smeared in glass slides and dyed using DiffQuick (Biopur Diagnosis) to
enable recognition of the nucleus and cytoplasm of the macrophages and
parasites. By this technique, the parasites in the lesions could be observed
and identified by the kinetoplast joined to the nucleus. Photographs were
taken in a Zeiss optical microscope at 40X.
2.3.8. Parasitic inhibition in the lesion
The number of parasites (amastigotes) remaining in the lesions after
the end of treatment was determined from macerates of the skin lesion
area. To obtain the amastigotes from the tissue, a protocol described in
Peralta et al [18] was followed. Briefly, 5 skin tissue samples were ho-
mogenized and the parasites were separated through mechanical tissue
disruption using a glass grinder. The percentage of parasite inhibition
with regard to controls was calculated as: (Total number of amastigotes
in treated group) x 100/(Total number of amastigotes in control group).
The viability of the remaining parasites was examined by using an
aliquot of each homogenate (1 mL) cultured in Difco blood agar
(USMARU) medium containing 20 % of defibrinated rabbit blood plus
P–S [19, 20] at 23 C under agitation. These cultures were then examined
for the presence of leishmania promastigotes after one week.
2.3.9. Statistical analysis
The results of lesion sizes and immunoglulin levels were analyzed
using the unpaired Mann-Whitney test, with p < 0.05 denoting signifi-
cant differences. GraphPad Prism (v.6) software was used for this anal-
ysis. The results are presented as means and standard error. The
macroscopic aspect of the lesions at the end of the treatments was plotted
as a percentage of case frequency for each experimental group.
3. Results and discussion
3.1. EuE-Ris-HPMC and Ris-HPMC hydrogels physicochemical
characterization
The preparation method produced translucid semisolid homogeneous
hydrogels of EuE-Ris-HPMC and Ris-HPMC without tendency for phase
separation, with an adequate viscosity that allowed easy expelling
through the syringe and manual administration.
EuE-Ris-HPMC hydrogels presented a pH value of 6.0  0.5, Ris-HPMC
hydrogel pH was 5  0.4. Zeta potential of EuE-Ris-HPMC was high and
positive (20.6  0.2) and Ris-HPMC zeta potential was 5.5  0.9.
Ris release towards physiological NaCl solution or water in bicom-
partmental Franz cells from all dispersions is shown in Figure 1. When
the receptor compartment was filled with water, a faster diffusion of Ris
from Ris-HPMC hydrogel was observed in comparison to the release from
EuE-Ris-HPMC hydrogel. When water in the receptor compartment was
replaced by a solution of NaCl, the release rate from the EuE-Ris-HPMC
hydrogel was significantly increased. Such behaviour can be associated
with the ionic exchange produced by the diffusion of Naþ and Cl to the3
donor compartment, which has been previously observed with other EuE
complexes [21, 22]. No modifications in release rate from Ris-HPMC
hydrogel were observed in NaCl vs water (Figure 1).
The presence of HPMC in Ris-HPMC and EuE-Ris-HPMC dispersions
slowed Ris release in bothmedia evaluated as compared to Ris solution or
EuE-Ris aqueous dispersion. Ris-HPMC dispersion slope was lower that of
Ris in water (Slope Ris-HPMC/Slope Ris ¼ 0.69) and in physiologic solu-
tion (Slope Ris-HPMC/Slope Ris ¼ 0.67). For EuE complexes, Slope EuE-
Ris-HPMC/Slope EuE-Ris were 0.8 and 0.54 in water and NaCl
respectively.
The decrease in the release rate of Ris in Ris-HPMC dispersions can be
related to the higher viscosity and hence a slower diffusion of Ris to the
receptor compartment. Drug diffusion depends on the crossover and
chain expansion of the polymers (i.e. increased viscosity and elasticity)
[23]. The presence of HPMC in EuE-Ris-HPMC dispersions also produced a
decrease in the release rate of Ris, but in this case the release mechanism
is dependent on ionic exchange and hence, when water was used as re-
ceptor media, the decrease was not significant.
The pH values of the receptor compartments recorded at the end of
the experiments were 4.4  0.3, 5.0  0.2 when water and physiological
solution, respectively, were used.
3.2. In vivo anti-leishmanial efficacy of hydrogels
As shown in Figure 2C, in this model of CL the mice develop a single
lesion, at the inoculation site. Topical Ris-HPMC and EuE-Ris-HPMC treat-
ment resulted in a reduction of the size of the lesions compared to un-
treated mice. In the group treated with EuE-Ris-HPMC, the lesions borders
started to partially flatten and the ulcer to show cicatrization from the
first week of treatment. From day 19, lesions had completely flattened
borders and no ulcers were visible in this group. We described this
behavior as 0 mm2 lesion area at days 19 and 22 in Figure 2A.
In the group treated with Ris-HPMC, the lesions started to flatten, show
cicatrization and diminish size at day 19. All the lesions treated with
either Ris-HPMC or EuE-Ris-HPMC showed an improvement in lesion
appearance, with flattened edges either in a part or in the complete
perimeter of the lesion, along with a recovery of the epidermis in the
previously ulcerated central region. At the end of treatment 100% and 50
% of the lesions treated with EuE-Ris-HPMC and Ris-HPMC, respectively,
showed flattened edges in the complete perimeter of the lesion and cic-
atrization of the ulcer (Figure 2B). Even in animals treated with Ris-HPMC
showing only a partially flattened edge, the ulcer showed cicatrization
(Figure 2B and C). While 60 % of untreated control mice developed ne-
crosis, this was never observed in the groups treated with Ris-HPMC or
EuE-Ris-HPMC. A marked parasitic inhibition in the lesions at the end of
treatment was found in the groups treated with Ris-HPMC or EuE-Ris-HPMC
(69.5 % and 73.7 % respectively, Table 1). No animals were kept alive
after treatment completion to evaluate recidivism, since we found
approx. 2 107 parasites in each lesion at the end of treatment. Since this
amount of parasites is enough to produce a recidiva of the lesion, the
animals cannot be considered cured.
Smears from the control group lesions revealed a higher amount of
amastigotes per field than those of Ris-HPMC and EuE-Ris-HPMC groups.
Both Ris-HPMC and EuE-Ris-HPMC groups showed development of pro-
mastigotes when the recovered lesions were cultured in USMARU, indi-
cating the presence of viable remaining parasites at the end of treatment.
However, the amastigotes found in the lesions treated with EuE-Ris-HPMC
showed vacuoles and a less compact nucleus (Figure 3A). The cyto-
plasmic vacuolization in the parasites treated with EuE-Ris-HPMC suggest
that autophagy is the mechanism underlying leishmania death [24].
However, specific experiments should be performed to confirm if EuE
itself is the responsible for this mechanism or it is potentiating Ris
anti-leishmanial activity.
Concerning the anti-leishmanial serum immunoglobulin levels, the
difference of IgG2a/IgG1 ratios was not significant between groups
although the ratios tended to increase in the treated groups after
Figure 2. Macroscopic appearance of lesions. A) Ulcer sizes in BALB/c mice infected with L. (L.) amazonensis after topical Ris-HPMC or EuE-Ris-HPMC treatment. Lesion
areas were determined using the formula: (L *W)/(4 *Π), where L and W are two perpendicular diameters. Lesions with completely flattened edges and no ulcers were
recorded as having 0 mm2 areas. **P < 0.005 (treatments vs control group). N ¼ 5. B) Percentage case frequency of lesions with flattened edges in the entire perimeter
of the lesion, partially flattened edges (only in part of the perimeter), ulcers or necrotic ulcers, determined from observations of the images. C) Representative photos
of each experimental group. Note the presence in the control lesion of a necrotic center. In the case of Ris-HPMC treated animals, the lesions edge persists in part of the
perimeter of the lesion (black arrow), but the ulcer appears closed. In EuE-Ris-HPMC treated animals, there is complete flattening of the lesion, ulcer cicatrization and
absence of protruding edges.
Figure 1. Risedronate release kinetics from different dispersions. Ris release from EuE-Ris-HPMC ( ) and Ris-HPMC ( ) towards water (A) and physiological NaCl so-
lution (B). EuE-Ris ( ) and RisNa ( ) water dispersions were used as references.
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progression of the disease seven weeks after infection normally shows
greatly increased IgG1 levels and decreased IgG2a levels [25]. This was
observed in the control untreated group. After treatment with Ris-HPMC or
EuE-Ris-HPMC, the IgG2a/IgG1 ratio continued to be lower than 1, which
is typical since normalization of the immune profile after treatment re-
quires a long time [26], and we measured the IgG levels immediately at
the end of treatment. However, the IgG2a/IgG1 ratio tended to increase
with the treatments, implying a tendency to a Th1 response. This is
crucial because the activation of infected macrophages produces leish-
manicidal products such as nitric oxide radicals, which are toxic for the
parasite [27, 28].
Other topical drugs, including imiquimod and amphotericin B, have
been tested in clinical trials, but results are equivocal and no major
breakthroughs have yet been achieved [29, 30]. Very recently, three
manuscripts have reported the good efficacy of topical Miltefosine or
Miltefosine/AnfotericineB dispersions in CL animal models produced by
different species of leishmania [31, 32, 33], including our own work
(M.F. Peralta, et al 2021) [15]. Leishmania is however a parasite that is
notable for showing a highly variable response to pharmacological
therapy, depending not only on species but even also on geographicalTable 1. Parasitic inhibition in BALB/c mice infected with L. (L.) amazonensis.
Amastigotes recovered from the lesions at the end of treatment and counted in an





parasite burden in lesions
Control 7.6  107 0
Ris-HPMC 2.3  107 69.5
EuE-Ris-HPMC 2.0  107 73.7
4
region. Consequently, the formulation of an effective pharmacotherapy
containing a different kind of drug such as Risedronate is extremely
important in the fight against the disease.
By flattening the borders of the lesions and eliminating ulcers, topical
Ris-HPMC was effective against L. (L.) amazonensis. We did not observe
significant differences between Ris-HPMC and EuE-Ris-HPMC regarding
parasitic burden decrease, but a clearly higher efficacy in healing the
lesions by EuE-Ris-HPMC was observed. This is especially important since
untreated lesions produce unsightly anthropic scars [34]. EuE may have
enhanced by itself the anti-leishmanial activity of Ris-HPMC in the com-
plex [13]. In order to verify this, in vitro studies should be performed.
Unfortunately, we were unsuccessful in performing in vitro studies due to
the insolubility of Ris and EuE-Ris in culture media since aminobi-
sphosphonates form insoluble complexes with calcium or other divalent
cations [14, 35] and EuE precipitates at pH values above 5 [36].
Although the release of Ris from EuE-Ris-HPMC was slower than from
Ris-HPMC, we observed a higher efficacy as anti-leishmanial, which may
be related to the complementary action of EuE. This increased activity
might be explained by the mode of action of individual components.
Recently, Gadelha et al. proposed a mechanism of action for Ris in
Leishmania infantum. Leishmania synthesizes ergosterol and Ris strongly
inhibits farnesyl diphosphate synthase (FPPS) enzyme, a key intermedi-
ate for ergosterol biosynthesis. Moreover, they observed that promasti-
gotes treated in vitro with Ris showed small vesicles in the Golgi region
near the kinetoplast, mitochondrial swelling, blebbing of the plasma
membrane, as well as nuclear pyknosis and chromatin condensation
[10]. They also reported phosphatidylserine (PS) exposure on the
membrane of the parasites, which indicates early apoptosis. In addition,
bisphosphonates have been shown to accumulate in tissues susceptible to
infection by some of these parasites and to possess immunomodulatory
effects [37].
In line with that observation, our in vivo results showed that lesions
treated with EuE-Ris-HPMC present vacuoles near the kinetoplast and
Figure 3. A) Optical microscopy images of smears from lesions. The intracellular amastigotes are identified by the rod-shaped kinetoplast and the circular nucleus in
lesion smears of the control group without treatment (A1), Ris-HPMC group (A2) and EuE-Ris-HPMC group (A3). The amplified sections (4x digitally amplified from
original images) show amastigotes morphology. B) Serum anti-leishmanial antibodies at the end of treatment. Ratio of IgG2a/IgG1 (Absorbance) levels found in the
serum of animals at the end of treatments. Measurements were obtained by ELISA. N ¼ 5.
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of the parasites (Figure 3 A3), suggesting that the combined therapy with
EuE and Ris can improve anti-leishmanial efficacy. Considering that EuE
is a polycation and EuE-Ris-HPMC presents a high and positive zeta po-
tential, an increased capability of interaction with the negatively charged
PS present in parasites membrane could be playing a role. In fact, once
EuE-Ris-HPMC reaches the macrophages vacuoles, the interaction with PS
can produce severe damage and parasite death [24, 38]. However, more
research is necessary to elucidate such mechanisms and to confirm if the
combined therapy produces additive or synergistic effects.
Cutaneous wound healing in mammals is a complex multi-step pro-
cess. It has also been suggested that microbes of lesions play significant
roles in impaired wound healing, i.e., in complex chronic injury,
microbiome have a detrimental effect on wound closure [39, 40]. A moist
wound environment is considered to promote the wound healing process,
favoring the granulation step. In our case, Ris-HPMC and EuE-Ris-HPMC
were dispersed in a hydrogel system containing polymers that could
facilitate the re-epithelialization process by diminishing water loss [41].
Besides, by causing a reduction of the parasite load, EuE-Ris-HPMC pre-
sumably had complementary effects in healing.
A re-epithelialization process of the ulcers was observed, but with
parasites still remaining in the dermis below the lesions, which may
imply a persistence/recurrence of the disease. The persistence of leish-
mania in skin or mucosal tissues was also reported in patients who ach-
ieved therapeutic cure of CL [42]. In fact, at present, the exact factors
related to parasite persistence or elimination are unknown.
Being highly polar, Ris is a molecule with a very low permeability
[43]. Thus, in order to reach dermal parasites it is probably necessary
that Ris application takes place while there is still an ulcer, when there
are no well-formed epidermal skin layers to penetrate. Thus, to improve
parasite reduction, the dosage or frequency of administration could be
increased, or combinations tried with other components of proven ac-
tivity. Meanwhile, the repurposing of both Ris and EuE for topical
treatment of CL is worth being explored.
This could be strategic since they are approved compounds, which
can reduce time, cost and risk, and it is a particularly attractive approach
for neglected tropical diseases where new medications are needed ur-
gently to treat the poorest of people, making their translation to clinical
use more feasible. In this sense, translational research, built on the solid
foundation of existing and ongoing basic research, is a priority.
4. Conclusions
The development of novel chemotherapeutic approaches for CL is of
great importance. The use of bisphosphonates is of interest as they have
already been used for other clinical indications. Ris produced moderately
encouraging results in the treatment of CL caused by L. (L.) amazonensis
in an experimental animal model. The EuE-Ris-HPMC complex led to
lesion cicatrization and a slightly higher reduction in the parasitic5
burden. Future work should be aimed at optimizing the concentration,
dose frequency, drug or excipient combinations and system characteris-
tics in order to attain total parasite elimination. To the best of our
knowledge, this is the first report on the efficacy of bisphosphonates
against CL as a topical treatment.
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